Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Post by JDavenporton Oct 28, 2022 6:02pm
251 Views
Post# 35057076

From the MD&A...

From the MD&A...
A couple of quiotes from the MD&A:

From page 2:

"Based on its current cash burn rate, the Company anticipates that its existing cash balance is sufficient to fund operations through approximately October 2022."

Looks like no deal soon. Also from page 2:

"As of September 30, 2022 the Company has a cash balance of $345,197. The Company has been reducing its research activities and deferring payments to its vendors in order to extend its cash. The Company is in discussions with Lind to modify the convertible security funding agreement, add additional repayment holidays, and lend the Company additional funds, in return for modified repayment terms. As of the date of this filing, the modification to the convertible security funding agreement has not been finalized. Additionally, as previously disclosed, the Company continues to pursue and evaluate strategic alternatives with its investment banking partner Ladenburg Thalmann. "
jd
<< Previous
Bullboard Posts
Next >>